Synergistic cytotoxicity between a protein kinase C inhibitor, UCN-01, and monoclonal antibody to the epidermal growth factor receptor on MDA-468 cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 12, Issue 2, 1997, Pages 117-121

  Tsuchida, Emiko ^a,b   Tsuchida, Masanori ^a   Urano, Muneyasu ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN KINASE C INHIBITOR; RECEPTOR ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; BREAST ADENOCARCINOMA; CARCINOMA CELL; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0030870459     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1997.12.117     Document Type: Article

References (19)

1. Nishizuka Y Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607.
2. Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy Cancer Invest 1991;9:553.
3. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991;47:87.
4. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation Nature 1988;334:661.
5. Margolis B, Rhee SG, Felder S, Mervic M, Lyall R, Levitzki A, Ullrich A, Zilberstein A, Schlessinger J. EGF induces tyrosine phosphorylation of phospholipase C-II: A potential mechanism for EGF receptor signaling. Cell 1989;57:1101.
6. 2 activation. Biochem J 1990;267:461.
7. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984;44:1002.
8. Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z, Koprowski H. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cell-independent effects. Cancer Res 1987;47:3692.
9. ++ dependent protein kinase. Biochem Biophys Res Commun 1986;135:397.
10. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models Cancer Res 1991;51:4888.
11. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53:2081.
12. Urano M, Reynolds R, Begley J. Protein kinase C inhibitor as a potent inhibitor of accelerated repopulation during radiotherapy: I. Growth inhibitory, cytotoxic, and indirect radiosensitizing effects of a Staurosporine derivative (UCN-01) in vitro. Radiat Oncol Invest 1995;3:64.
13. Filmus J, Pollak MN, Cailleau R, Buick RN. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 1985,128:898.
14. Ennis BW, Valverius EM, Bates SE, Lippman ME, Bellot F, Kris R, Schlessinger J, Masui H, Goldenberg A, Mendelsohn J, Dickson RB. Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol 1989;3:1830.
15. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984;259:7755.
16. Schlessinger J. Allosteric regulation of the epidermal growth factor receptor kinase. J Cell Biol 1986;103:2067.
17. Capone PM, Papsidero LD, Chu TM. Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors. JNCI 1984;72:673.
18. Takahashi I, Saitoh Y, Yoshida M, Sano H, Nakano H, Morimoto M, Tamaoki T. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J Antibiot 1989;42:571.
19. Wang Q, Worland PJ, Clark JL, Carlson BA,Sausville EA. Apoptosis in 7-hydroxystauro-sporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth & Differ 1995;6:927.